Reducing CV risk for patients with type 2 diabetes – latest evidence for diabetes medications
These meetings are intended for UK Healthcare Professionals and have been developed in accordance with the ABPI Code of Practice.
PM Healthcare events are Quality Assured by the University of Bradford
| Satellite | Reducing CV risk for patients with type 2 diabetes – latest evidence for diabetes medications | |||
| Speakers | Barry Keenan, Senior Clinical Pharmacist, South West Acute Hospital, WHSCT | |||
| Satellite Description | ||||
|
This session aims to help the audience understand the link between type 2 diabetes and cardiovascular disease and how the residual risk of cardiovascular disease associated with type 2 diabetes can be minimised through a multifactorial approach. The session will also review the emerging evidence with respect to blood glucose lowering therapies and their impact on cardiovascular risk. Novo Nordisk has organised and fully funded the 'Reducing CV risk for patients with type 2 diabetes - latest evidence for diabetes medications' symposium for this meeting. Novo Nordisk products will be discussed during this symposium and prescribing information will be available. UK/VT/0318/0158 Date of preparation February 2018
| ||||
| Sponsored By | Novo Nordisk Ltd | |||
